v3.25.4
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Jan. 31, 2026
Jun. 30, 2025
Cover [Abstract]        
Document Type 10-K      
Amendment Flag false      
Document Period End Date Dec. 31, 2025      
Document Fiscal Year Focus 2025      
Document Fiscal Period Focus FY      
Trading Symbol VKTX      
Entity Registrant Name Viking Therapeutics, Inc.      
Entity Central Index Key 0001607678      
Current Fiscal Year End Date --12-31      
Entity Well-known Seasoned Issuer Yes      
Entity Current Reporting Status Yes      
Entity Voluntary Filers No      
Entity Filer Category Large Accelerated Filer      
Entity Small Business false      
Entity Emerging Growth Company false      
Document Financial Statement Error Correction [Flag] false      
Entity Shell Company false      
Entity Common Stock, Shares Outstanding     115,554,295  
Entity Public Float       $ 2,976,737,289
Entity Interactive Data Current Yes      
Title of 12(b) Security Common Stock, par value $0.00001 per share      
Security Exchange Name NASDAQ      
Entity File Number 001-37355      
Entity Incorporation, State or Country Code DE      
Entity Tax Identification Number 46-1073877      
Entity Address, Address Line One 9920 Pacific Heights Blvd      
Entity Address, Address Line Two Suite 350      
Entity Address, City or Town San Diego      
Entity Address, State or Province CA      
Entity Address, Postal Zip Code 92121      
City Area Code 858      
Local Phone Number 704-4660      
Document Annual Report true      
Document Transition Report false      
ICFR Auditor Attestation Flag true      
Documents Incorporated by Reference

Portions of the Registrant’s Definitive Proxy Statement for its 2026 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2025 are incorporated by reference into Part III of this Annual Report on Form 10-K.

      
Auditor Firm ID 199 688    
Auditor Name CBIZ CPAs P.C. Marcum llp    
Auditor Location Costa Mesa, California Costa Mesa, California    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Viking Therapeutics, Inc. (the “Company”) as of December 31, 2025, the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”).

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the Company's internal control over financial reporting as of December 31, 2025 based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 and our report dated February 11, 2026, expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Viking Therapeutics, Inc. (the “Company”) as of December 31, 2024, the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.